Peter Loftus

“Not for the squeamish.” The Mütter Museum has been collecting human body parts for 160 years. A tumor its donor named “Helga the Destroyer” is stuck in storage while the museum debates its future. Don't miss this @Loftus Ahed! wsj.com/lifestyle/mutt… @WSJ #philanthropy#museum

Friends of a free press: Please read and share our article about Evan Gershkovich of The Wall Street Journal, the distinguished U.S. journalist unjustly detained by Russia. wsj.com/articles/wsj-r….

Editors of more than three dozen news organizations signed a letter calling for the release of Wall Street Journal reporter Evan Gershkovich #IStandwithEvan wsj.com/articles/leade… via @WSJ

Breaking: Drugmaker Sanofi plans to cut the prices of its insulin products by up to 78% and cap the cost for patients taking one of the products at $35 a month. wsj.com/articles/diabe…

Novartis AG notified doctors it cannot fill new orders for a drug shown to extend lives of advanced prostate cancer patients. Some patients have no other treatment option. “People will die from this shortage, for sure,” Dr. Jonathan McConathy said. wsj.com/articles/short…

Breaking: Novo Nordisk, a large insulin maker, plans to cut the prices of its widely used products up to 75% to make them more affordable for patients, ⁦@Loftus⁩ reports wsj.com/articles/insul…

The Journal podcast about testing drugs for fentanyl featuring @littlewern wsj.com/podcasts/the-j…

Struggles to find a permanent head of the important NIH, from @l_e_whyte and @StephArmour1 : wsj.com/articles/nih-t…

Big news day including comprehensive coverage of SVB, but I’d also like to single out some great work by my WSJ Health & Science colleagues featured prominently on WSJ.com right now...

@nathanvardi @BiologyFool @ArmstrongDrew @Frank_S_David Agreed, thank you.

@BiologyFool @ArmstrongDrew @Loftus @Frank_S_David That's good company to be in. Thanks, Brian.

📚Biotwitter: If you were going to put together a reading list for a new-to-the-industry journalist, of non-fiction books about biotech, drugs, the industry + science/medicine, what would you put on it?

Please tune in tomorrow for this live Q&A with @jonathanrockoff to discuss ‘The Messenger,' my book about Moderna wsj.com/live-qa/peter-…

Feb. 7! WSJ reporter/author Peter @Loftus and WSJ health biz editor @jonathanrockoff discuss Peter's new book about Moderna and the Covid-19 vaccine. Watch here: wsj.com/live-qa #WSJHealth

Rain? What rain? Good morning San Francisco, gearing up for #JPM23

@DrugChannels @WSJ @icer_review Thanks Adam

Good @WSJ story about how expensive, one-time gene therapies stress our fragmented insurance system. Even @icer_review concedes that multi-million therapies can be cost effective--but employers resist paying for long-term benefits @Loftus drugch.nl/3Vn87Gz

@Jasonmmast Good find!

Was surprised to see the name of Lillys new experimental Alzheimer’s antibody — remternetug — didn’t end in “mab,” as all antibody drugs do Learned that, apparently, the 3-decade era of “mab” ended last year, as scientists just ran out of new names(???) ncbi.nlm.nih.gov/pmc/articles/P…

For years RSV eluded efforts to find a vaccine, but an NIH research breakthrough helped set the stage for the current crop of candidates: wsj.com/articles/pfize…

A respiratory virus, RSV, is a main culprit. Companies are racing to make vaccines against it: wsj.com/articles/gsk-p…

Physicians are reporting unseasonably high numbers of respiratory illnesses in kids, straining many children’s hospitals before the typically busier winter months wsj.com/articles/a-sur… via @WSJ @Brabbott42 @jdeavila